Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 8/10/20 → 1/30/27 |
Financiación
- Merck Sharp & Dohme Corporation: 198.704,00 US$
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants
- Hao, Zhonglin (PI)
- Zinner, Ralph (Former PI)